Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

General Information

Starpharma Holdings Limited
SPL
http://www.starpharma.com
Pharmaceuticals
230
319

Current Price Data+

Current Price Open High Low Last Close Volume Price Movement
$0.72 $0.77 $0.77 $0.71 $0.76 97308 $0.04 ( 5.26% )
  • +Security prices are delayed by least 20 minutes and are indicative only.

Current Broker Consensus Recommendation

Strong Buy
02/07/2015
1

Company Overview

Business Description
Starpharma Holdings Limited (SPL) is a biotechnology company that engages in the development of dendrimer products for pharmaceutical, life science and other applications. SPL's underlying technology is built around dendrimers, a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical uses. SPL has three core development programs: VivaGel portfolio, drug delivery, and agrochemicals.
Strategy Analysis
Starpharma Holdings reported a net loss of $1.83m for the half-year ended 31 December 2012. Revenues from ordinary activities were $1.29m, up 24% from last year. Basic and Diluted EPS was (1.0) cent compared to (2.0) cents last year. The net operating cash outflow was $10.24m compared to an outflow of $3.9m in the pcp. No dividend was declared.

Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2016 F 0.0 -0.5 0.0% 0.0 0.0 0.0% 0.0%
2015 F 0.0 -5.9 0.0% 0.0 0.0 0.0% 0.0%
2014 A -14.6 -5.2 0.0% 0.0 0.0 0.0% 0.0%

Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2014 A 2015 F 2016 F 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F
Acrux Limited (ACR) $144M 3.0384 -0.6024 0.2934 5.1488 12.9491 10.0116 9.25% 9.25% 9.25%
Mayne Pharma Group (MYX) $814M 1.0457 -0.2428 1.2068 33.0671 43.6709 19.7897 0.00% 0.00% 0.00%
Starpharma (SPL) $243M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

Financial Summary

Earnings P/E Ratio P/B Ratio P/E Growth
Company 3.00 0.00 6.23 0.00
Market 0.91 16.10 1.33 1.27
Sector 0.90 13.20 3.12 0.95

Directors

Name Position Start Date
Dr Jacinth (Jackie) Kincaid Fairley Chief Executive Officer, Executive Director 01/07/2006
Dr Peter J Jenkins Non-Executive Deputy Chairman, Non-Executive Director 13/05/1997
Ms Zita Peach Non-Executive Director 01/10/2011
Mr Peter R Turvey Non-Executive Director 19/03/2012
Mr Richard A Hazelton Non-Executive Director 01/12/2006
Mr Robert Bain Thomas Non-Executive Director, Non-Executive Chairman 04/12/2013

Management

Name Position
Nigel Baade Chief Financial Officer,Company Secretary
A Eglezos VP, Business Development
C P Barrett VP, Business Development
J R Paull VP, Development and Regulatory Affairs
D J Owen VP, Research

Substantial Shareholders

Holding Name
41,319,032 (14.49%) Allan Gray Australia Pty Ltd
37,069,789 (13%) M&G Investment Funds
26,357,951 (9.24%) Acorn Capital Limited
14,406,827 (5.05%) The Dow Chemical Company

Calendar of Events

Date Event
15 February 2016 Report (Interim)
12 August 2015 Report (Prelim)
12 August 2015 Report (Annual)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.